

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Mesalazine Salazosulfapyridine

September 9, 2025

Therapeutic category

Other agents affecting digestive organs

Sulfonamide preparations

Non-proprietary name

Mesalazine

Salazosulfapyridine

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis</u> <u>General symptoms, such as pyrexia, malaise, arthralgia, and</u> <u>myalgia, and organ symptoms such as erythema, purpura (derma),</u> <u>bloody sputum (lung), haematuria, and proteinuria (kidney), may</u> <u>occur.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.